This HTML5 document contains 95 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n30http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/chebi/
n28http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/wikipedia/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/pdb/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00903/identifier/drugbank/
n29http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00903
rdf:type
n3:Drug
n3:description
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. [PubChem]
n3:dosage
n22:271B5C0A-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.
n3:manufacturer
n5:271B5C05-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00903 n28:DB00903
dcterms:title
Ethacrynic acid
adms:identifier
n9:Ethacrynic_acid n10:PA449518 n11:3278 n12:0006-0065-68 n13:EAA n14:46507562 n15:4876 n17:D00313 n18:3163 n19:DB00903
n3:mechanismOfAction
Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.
n3:packager
n5:271B5C02-363D-11E5-9242-09173F13E4C5 n5:271B5C03-363D-11E5-9242-09173F13E4C5 n5:271B5C04-363D-11E5-9242-09173F13E4C5 n5:271B5C01-363D-11E5-9242-09173F13E4C5 n5:271B5BFF-363D-11E5-9242-09173F13E4C5 n5:271B5C00-363D-11E5-9242-09173F13E4C5 n5:271B5BFE-363D-11E5-9242-09173F13E4C5
n3:synonym
Taladren Hydromedin Ethacrynic acid (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid Methylenebutyrylphenoxyacetic acid Edecrina Hidromedin Etakrinic acid Endecril Acide etacrynique Ethacryinic Acid Acidum etacrynicum Uregit Mingit Ethacrynate Reomax Acido etacrinico Crinuryl Etacrinic acid Etacrynic acid Otacril Edecril
n3:toxicity
Overdosage may lead to excessive diuresis with electrolyte depletion.
n6:hasAHFSCode
n7:40-28-08
n3:foodInteraction
Take with food to reduce irritation.
n3:proteinBinding
> 98%
n3:synthesisReference
Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.
n26:hasConcept
n27:M0007812
foaf:page
n21:ethacrynate-sodium.html n30:edecrin.htm
n3:IUPAC-Name
n4:271B5C0F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C15-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C14-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C11-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C12-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C13-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C0D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C0E-363D-11E5-9242-09173F13E4C5 n4:271B5C0B-363D-11E5-9242-09173F13E4C5 n4:271B5C26-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C0C-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5C27-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n29:C03CC01
n3:H-Bond-Acceptor-Count
n4:271B5C1B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C1C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C16-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C17-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C19-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C18-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C1A-363D-11E5-9242-09173F13E4C5
n3:absorption
Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
58-54-8
n3:category
n3:containedIn
n25:271B5C08-363D-11E5-9242-09173F13E4C5 n25:271B5C06-363D-11E5-9242-09173F13E4C5 n25:271B5C07-363D-11E5-9242-09173F13E4C5 n25:271B5C09-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5C21-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C23-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C24-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5C25-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C20-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C1F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C22-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C10-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C1D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C1E-363D-11E5-9242-09173F13E4C5